List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 11 studies with search of: prostate cancer, psma, treat
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
Condition: Prostate Cancer
Intervention: Biological: peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant)
2 Active, not recruiting Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel
Condition: Prostate Cancer
Intervention: Biological: rsPSMA protein plus Alhydrogel® vaccine
3 Terminated Study of a Drug [DCVax (Tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is No Longer Effective.
Condition: Prostate Cancer
Intervention: Drug: Dendritic cell immunotherapy
4 Active, not recruiting Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Condition: Prostate Cancer
Interventions: Biological: PSA prostate cancer vaccine;   Biological: recombinant interleukin-12
5 Active, not recruiting Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Condition: Prostate Cancer
Interventions: Biological: PSA prostate cancer vaccine;   Biological: therapeutic autologous dendritic cells
6 Active, not recruiting GVAX in Advanced Prostate Cancer Patients Made Lymphopenic
Condition: Prostate Cancer
Intervention: Biological: GM-CSF gene transduced allogeneic vaccine GVAX
7 Recruiting Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Condition: Prostate Cancer
Intervention: Biological: Gene Modified T Cells
8 Recruiting Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Docetaxel;   Drug: Prednisone;   Drug: 177Lu-J591
9 Recruiting RNActive®-Derived Therapeutic Vaccine
Condition: Hormone Refractory Prostate Cancer
Intervention: Biological: CV9103
10 Active, not recruiting Vaccine Therapy in Treating Patients With Kidney Cancer
Condition: Kidney Cancer
Interventions: Biological: human prostate-specific membrane antigen plasmid DNA vaccine;   Biological: mouse prostate-specific membrane antigen plasmid DNA vaccine
11 Active, not recruiting Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Conditions: Ovarian;   Melanoma;   Renal;   Prostate;   Colorectal;   Endometrial Carcinoma;   Cervical Carcinoma;   Testicular Cancer;   Thyroid Cancer;   Small Cell Lung Carcinoma;   Mesothelioma;   Breast Carcinoma;   Esophageal Carcinoma;   Gastric Cancer;   Pancreatic Carcinoma;   Neuroendocrine Cancer;   Liver Cancer;   Gallbladder Cancer;   Biliary Tract Cancer;   Anal Carcinoma;   Bone Sarcomas;   Soft Tissue Sarcomas;   Carcinoma of Unknown Origin, Primary
Intervention: Biological: PSMA/PRAME

Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services